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OBJECTIVE—Polycystic ovary syndrome (PCOS) is associated
with the metabolic syndrome. Decreased omentin-1 levels are
associated with obesity and diabetes. To study the effects of
metformin treatment on omentin-1 levels in PCOS subjects and
effects of omentin-1 on in vitro migration and angiogenesis.
RESEARCH DESIGN AND METHODS—Serum omentin-1
was measured by ELISA. Angiogenesis was assessed by studying
capillary tube formation in human microvascular endothelial
cells (HMEC-1) on growth factor reduced Matrigel. Endothelial
cell migration assay was performed in a modiﬁed Boyden cham-
ber. Nuclear factor-B (NF-B) was studied by stably transfect-
ing HMEC-1 cells with a cis-reporter plasmid containing
luciferase reporter gene linked to ﬁve repeats of NF-B binding
sites. Akt phosphorylation was assessed by Western blotting.
RESULTS—Serum omentin-1 was signiﬁcantly lower in PCOS
women (P  0.05). After 6 months of metformin treatment, there
was a signiﬁcant increase in serum omentin-1 (P  0.01).
Importantly, changes in hs-CRP were signiﬁcantly negatively
correlated with changes in serum omentin-1 (P  0.036). In vitro
migration and angiogenesis were signiﬁcantly increased in serum
from PCOS women (P  0.01) compared with matched control
subjects; these effects were signiﬁcantly attenuated by met-
formin treatment (P  0.01) plausibly through the regulation of
omentin-1 levels via NF-B and Akt pathways. CRP and VEGF
induced in vitro migration, and angiogenesis was signiﬁcantly
decreased by omentin-1.
CONCLUSIONS—Increases in omentin-1 levels may play a role
but are not sufﬁcient to explain the decreased inﬂammatory and
angiogenic effects of sera from metformin-treated PCOS women.
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P
olycystic ovary syndrome (PCOS) is a proinﬂam-
matory state associated with type 2 diabetes,
visceral obesity, and cardiovascular complica-
tions, features of the metabolic syndrome (1–5).
The metabolic syndrome is associated with accumulation
of visceral adipose tissue. Visceral adipose tissue pro-
duces cytokines termed “adipokines” implicated in the
pathogenesis of diabetes and atherosclerosis (6–9).
Omentin-1 has been described as a novel adipokine
preferentially produced by visceral adipose tissue. In vitro
experiments revealed that treatment with recombinant
omentin-1 enhances insulin-stimulated glucose uptake in
human adipocytes. Also, omentin-1 was shown to trigger
Akt signaling in both the absence and presence of insulin
(10,11). Additionally, omentin plasma levels and omentin
gene expression in visceral adipose tissue are decreased in
obesity (12). Recently, we have reported novel data show-
ing a signiﬁcant decrease of adipose tissue and circulating
omentin-1 levels in overweight PCOS women (13). Thus,
given the above functions of omentin-1, increasing omen-
tin-1 levels in PCOS women may alleviate cardiometabolic
dysfunction in these women.
We studied the effects of metformin treatment on omen-
tin-1 levels in PCOS subjects and effects of omentin-1 and
serum on in vitro migration and angiogenesis. Researchers
have used serum to perform functional experiments in
endothelial, cardiac, and neural cells (14–16). Finally,
given the link between inﬂammation and angiogenesis
(17), we explored nuclear factor-kappaB (NF-B), Erk1/2,
and Akt pathways, important regulators of inﬂammation
and angiogenesis (18,19).
RESEARCH DESIGN AND METHODS
All PCOS patients met all three criteria of the revised 2003 Rotterdam
European Society of Human Reproduction and Embryology (ESHRE)/Ameri-
can Society of Reproductive Medicine (ASRM) PCOS Consensus Workshop
Group diagnostic criteria. The three criteria are 1) oligo- and/or anovulation,
2) clinical and/or biochemical signs of hyperandrogenism, and 3) polycystic
ovaries (20). Furthermore, all subjects in the control arm had normal ﬁndings
on pelvic ultrasound scan, regular periods, and no hirsutism/acne. The control
group had no discernible cause for infertility (unexplained infertility). No
women were amenorrheic. All subjects that were studied did not have
endometriosis. Exclusion criteria for the study included age  40 years,
known cardiovascular disease, thyroid disease, neoplasms, current smoking,
diabetes, hypertension (blood pressure  140/90 mmHg), and renal impair-
ment (serum creatinine  120 mol/l). None of these women were on any
medications for at least 6 months prior to the study, including oral contra-
ceptives, glucocorticoids, ovulation induction agents, antidiabetic and anti-
obesity drugs, and estrogenic, antiandrogenic, or antihypertensive medication.
All patients underwent anthropometric measurements. Blood pressure was
measured in a sitting position within a quiet and calm environment after a rest
of at least 5 min. The average of three measurements was obtained. Subjects
were outpatients of the Department of Reproductive Medicine and Gynaeco-
logical Endocrinology of Magdeburg University and the Department of Ob-
stetrics and Gynaecology of Martin-Luther-University Halle. The metabolic
study was performed in the Outpatient Department of Endocrinology and
Metabolism of Magdeburg University. Blood samples were collected between
0800 and 0900 h, after a 3-day normal carbohydrate diet and an overnight fast.
Blood samples were drawn into serum separator tubes that contain no
additives or anticoagulants, allowed to clot, centrifuged (3,000 rpm for 10 min)
to separate sera, and stored at 80°C.
A treatment with metformin in an “off-label use” was offered to all PCOS
women independently from the results of insulin sensitivity testing. In those
PCOS women that agreed, therapy was initiated after basal assessment, and
the dose of metformin was increased to a maintenance dose of 850 mg twice
daily. All patients underwent anthropometric measurements before and after
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PCOS subjects, before and after metformin (see below). A total of 83 women
of Caucasian origin with PCOS were recruited, 49 of which did not participate
in the metformin arm of the study. The baseline characteristics of the 49 PCOS
women were comparable to the 34 PCOS women who participated in the
metformin arm of the study. Furthermore, the 21 women who completed the
metformin arm of the study were comparable to the 13 PCOS women who did
not complete the metformin arm of the study. For the purposes of elucidating
the effects of metformin in PCOS women, the 21 PCOS subjects were studied.
The study design was approved by the Local Research Ethics Committee
of the University of Magdeburg, and written informed consent was obtained
from all participants, in accordance with the guidelines in The Declaration of
Helsinki 2000.
Intima media thickness. Measurement of carotid IMT is a widely accepted
tool to provide information about preclinical vascular disease. B-mode
sonography of the proximal part of the carotid bulb was conducted on both
sides, and the segments of the common carotid arteries 1.0 cm proximal were
scanned longitudinally with Hitachi EUB-5000 plus-G (Hitachi Ltd., Tokyo,
Japan) using a 10-MHz linear-array transducer. All women were investigated
in a supine position with the head slightly hyperextended and turned away
from the side being scanned. The image was focused on the posterior wall,
and the resolution function was used to magnify the arterial far wall. When an
optimal image was obtained, it was frozen, and the distance from the junction
of the lumen and intima and the junction of the media and adventitia was
measured by electronic calipers in end-diastolic phase, to minimize variability
during the cardiac cycle. All images were photographed. Five measurements
were conducted on each side, and the mean IMT was calculated as the average
of these measurements. All measurements were performed by an experienced
ultrasound sonographer (intra-observer coefﬁcient of variation was 6.8%) who
was blinded to the diagnosis of subjects.
Biochemical and hormonal analysis. Assays for glucose, insulin, choles-
terol, triglycerides, luteinizing hormone, follicular stimulating hormone,
testosterone, and rostenedione, dehydroepiandrosterone-sulfate, and sex hor-
mone–binding globulin were performed using an automated analyzer (Abbott
Architect, Abbott Laboratories, Abbott Park, USA). The estimate of insulin
resistance by homeostasis model assessment (HOMA-IR) score was calcu-
lated as previously described (21). High-sensitivity C-reactive protein (hs-
CRP) was determined immunoturbidimetrically using a modular system
random-access analyzer (Roche Diagnostics). Omentin-1 levels in sera were
measured using a commercially available ELISA kit (AXXORA, Nottingham,
U.K.), according to manufacturer’s protocol, with an intra-assay coefﬁcient of
variation of 6%.
Immunodepletion of serum omentin-1 and CRP. Immunodepletion of
serum omentin-1 and CRP were performed using the immunoprecipitation
protocol provided by Dr. Kazuyuki Itoh and Montecucco et al., respectively
(14,22). One ml of human serum was incubated with mouse-anti-human
omentin-1 IgG-protein G-Sepharose conjugate (1–2 g/100–500 g of total
protein) or control mouse IgG-protein G-Sepharose conjugate; goat-anti-
human CRP IgA-protein A-Sepharose conjugate (10 g/100–500 g of total
protein) or control goat IgA-protein A-Sepharose conjugate, mixed overnight
at 4°C and centrifuged to sediment the conjugated Sepharose beads. The
supernatants were collected, and similar procedures were repeated eight
times. Supernatants and sera were subjected to immunoblotting for omentin-1
as previously described (13). Immunoblotting for CRP is described below.
Immunoblotting conﬁrmed that these protocols decreased serum omentin-1
and CRP by 80% (data not shown), respectively.
Endothelial cell culture. Human microvascular endothelial cells (HMEC-1)
were obtained from the Center for Disease Control, Atlanta, USA HMEC-1
cells were cultured in MCDB medium (Sigma-Aldrich, Gillingham, U.K.)
supplemented with 10% fetal calf serum (Sigma-Aldrich, Gillingham, U.K.), 100
IU/ml penicillin (Sigma-Aldrich, Gillingham, U.K.), 100 g/ml streptomycin
(Sigma-Aldrich), 5 ml of 200 mmol/l L-glutamine/500 ml of media, hydrocorti-
sone 2 mol/l, and epidermal growth factor 2 ng/ml (Invitrogen, Paisley, U.K.)
at 37°C in 5% CO2/95% air. Prior to each experiment, cells were fed with MCDB
with addition of 1% fetal calf serum for 16 h.
For endothelial cell signaling experiments, HMECs were preincubated with or
without omentin-1 (Kamiya Biomedical Company, Seattle, USA) for 30 min
followed by treatment with or without 1% of human serum from normal (n  39;
individually tested) and PCOS women [before (n  21; individually tested) and
after (n  21; individually tested) 6 months of metformin treatment] at different
time points (0, 2, 5, 10, 20, 30, and 60 min). Dose- and time-dependent experiments
were performed to determine the optimum concentration and time point.
In vitro angiogenesis assay. Angiogenesis was assessed by studying the
formation of capillary tubelike structures by culturing HMEC-1 cells on
growth factor reduced Matrigel (BD Biosciences, San Jose, USA). Matrigel
was coated onto the culture plates as per manufacturer’s instructions.
HMEC-1 cells were preincubated with or without omentin-1 (Kamiya Biomed-
ical Company, Seattle, USA) and/or with or without PI3K/Akt inhibitor
(LY294002) (Calbiochem, San Diego, USA) for 30 min and 1 h, respectively,
followed by treatment with or without 1% of human serum from normal (n 
39; individually tested) and PCOS women [before (n  21; individually tested)
and after (n  21; individually tested) 6 months of metformin treatment] or
CRP or omentin-1 [PCOS after metformin (n  21; individually tested)] and
CRP [PCOS before metformin (n  21; individually tested)] immunodepleted
sera. Vascular endothelial growth factor (VEGF) served as positive control.
Trypsinized HMEC-1 cells were then seeded onto the Matrigel-coated plates at
a density of 4–5  10
3/well in fresh media and incubated at 37°C. Dose- and
time-dependent experiments were performed to determine the optimum
concentration and time point. Capillary tube formation images were captured
with a digital microscope camera system (Olympus, Tokyo, Japan). Image Pro
Plus software was used to quantify tube length formation; the lengths of tubes
in 3–4 randomly selected ﬁelds in each of the wells were measured (23–26).
In vitro migration assay. Endothelial cell migration assay was performed in
a modiﬁed Boyden chamber using a protocol obtained from BD BioCoat
Angiogenesis System (BD Biosciences, San Jose, USA). Endothelial cells were
trypsinized; a cell suspension of 4  10
5 cells/ml was prepared, 250 l of which
was added to each of the trans-well inserts. Starvation media (750 l) was
added to the lower chamber and incubated overnight. After this, the cells were
labeled by incubating with Hank’s balanced salt solution medium (Sigma-
Aldrich, Gillingham, U.K.) containing 4 g/ml Calcein-AM (BD Biosciences,
San Jose, USA) for 90 min. The cells were preincubated with or without
omentin-1 (Kamiya Biomedical Company, Seattle, USA) and/or with or with-
out PI3K/Akt inhibitor (LY294002) (Calbiochem, San Diego, USA) for 30 min
and 1 h, respectively, followed by treatment with or without 1% of human
serum from normal (n  39; individually tested) and PCOS women [before
(n  21; individually tested) and after (n  21; individually tested) 6 months
of metformin treatment] or CRP or omentin-1 [PCOS after metformin (n  21;
individually tested)] and CRP [PCOS before metformin (n  21; individually
tested)] immunodepleted sera. VEGF served as positive control. Dose- and
time-dependent experiments were performed to determine the optimum
concentration and time point. Cells were ﬁxed with 2% formaldehyde.
Fluorescence of migrated cells was read in a ﬂuorescence plate reader with
bottom reading capabilities at excitation/emission wavelengths of 494/517 nm.
Only those labeled cells that have migrated through the pores of the
membrane will be detected (23–26).
NF-B activation. We studied NF-B activation by stably transfecting HMEC-1
cells with a cis-reporter plasmid containing luciferase reporter gene linked to ﬁve
repeats of NF-B binding sites (pNF-B-Luc; Stratagene, LA Jolla, USA). Multiple
clones were selected for the analysis of NF-B activation. HMEC-1 cells were
preincubated with or without omentin-1 (Kamiya Biomedical Company, Seattle,
USA) for 30 min followed by treatment with or without 1% of human serum from
normal (n  39; individually tested) and PCOS women [before (n  21;
individually tested) and after (n  21; individually tested) 6 months of metformin
treatment] or CRP or omentin-1 [PCOS after metformin (n  21; individually
tested)] and CRP [PCOS before metformin (n  21; individually tested)] immu-
nodepleted sera for 2 h. Cells were lysed, and luciferase activities were measured.
Experiments were also performed with TK plasmid (Promega, Southampton,
U.K.) as negative control and tumor necrosis factor 	 (TNF-	) as positive control.
Dose- and time-dependent experiments were performed to determine the opti-
mum concentration and time point.
Western blotting. Endothelial cells were lysed with SDS sample buffer (5 mol/l
urea, 0.17 mol/l SDS, 0.4 mol/l dithiothreitol, and 50 mmol/l Tris-HCl, pH 8.0),
mixed, sonicated, boiled, centrifuged (5,000 rpm for 2 min), and then stored at
80°C until use. Eighty g of each sample, supernatants, and sera were subjected
to SDS-PAGE (8% resolving gel) and transferred to polyvinylidene ﬂuoride
(PVDF) membranes. PVDF membranes were blocked in Tris-buffered saline
containing 0.1% Tween-20 and 5% BSA for 2 h. The PVDF membranes were then
incubated with polyclonal primary rabbit-anti-human antibody for phospho-
Erk1/2 (Cell Signaling Technology Inc., Beverly, USA) (1:1,000 dilution) or
polyclonal primary rabbit-anti-human antibody for phospho-Akt (Ser473) (Cell
Signaling Technology Inc., Beverly, USA) (1:1,000 dilution) or monoclonal pri-
mary goat-anti-human antibody for CRP (Sigma-Aldrich, Gillingham, U.K.) (1:
1,000 dilution) overnight at 4°C. The membranes were washed thoroughly for 60
min with Tris-buffered saline–0.1% Tween before incubation with the secondary
anti-rabbit horseradish peroxidase-conjugated immunoglobulin (Dako, Ely, U.K.)
(1:2,000) or secondary anti-goat horseradish peroxidase-conjugated immunoglob-
ulin (Dako, Ely, U.K.) (1:2,000) for1ha troom temperature. Antibody complexes
were visualized using chemiluminescence (ECL
; GE Healthcare, Little Chalfont,
U.K.). For standardization, the same membranes were stripped and reprobed
using polyclonal primary rabbit-anti-human antibodies for total Erk1/2 (Cell
Signaling Technology Inc., Beverly, USA) [1:1,000 dilution] or total Akt (Cell
Signaling Technology Inc., Beverly, USA) [1:1,000 dilution].
The densities were measured using a scanning densitometer coupled to
scanning software Scion Image (Scion Corporation, Frederick, USA). Stan-
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range of protein amounts loaded into gel lanes. Comparisons of densitometric
signal intensities for phospho-Erk1/2, phospho-Akt, total Erk1/2, and total Akt
were made only within this linearity range.
Statistics. Data were analyzed by Mann–Whitney U test or Kruskal–Wallis
ANOVA (post hoc analysis: Dunn’s test) according to the number of groups
compared. Data are medians (interquartile range). Spearman rank correlation
was used for calculation of associations between variables. If individual
bivariate correlations achieved statistical signiﬁcance, multiple regression
analysis with omentin-1 as dependent variable was performed to test the joint
effect of these parameters on omentin-1. P  0.05 was considered signiﬁcant.
RESULTS
Table 1 shows the anthropometric, biochemical, and hor-
monal data in all subjects. Insulin, HOMA-IR, cholesterol,
triglycerides, luteinizing hormone, testosterone, free andro-
gen index, systolic blood pressure, diastolic blood pressure,
IMT, and hs-CRP were signiﬁcantly higher whereas dehydro-
epiandrosterone-sulfate and sex hormone–binding globulin
were signiﬁcantly lower in PCOS women.
Serum omentin-1 levels were signiﬁcantly lower in
PCOS subjects compared with control subjects [23.7
(20.0–27.9) versus 27.6 (25.6–29.4) ng/ml; P  0.05: Table
1]. Serum progesterone levels in all women conﬁrmed
follicular phase of the menstrual cycle.
Table 2 shows the effects of metformin treatment on
TABLE 1
Clinical, hormonal, and metabolic features of women with PCOS and control subjects
Variable PCOS (n  21)
Control subjects
(n  39) Signiﬁcance
Age (years) 28 (26.5–31.5) 28 (23–32) NS
BMI (kg/m
2) 32.8 (29.8–36.5) 29.1 (27.3–34.1) NS
WHR 0.82 (0.76–0.88) 0.81 (0.78–0.86) NS
Glucose (mmol/l) 5.1 (4.7–5.5) 4.8 (4.4–5.1) NS
Insulin (pmol/l) 70.0 (54.5–94.5) 41.0 (32.0–55.0) P  0.01
HOMA-IR 2.2 (2.0–3.0) 1.2 (1.0–1.7) P  0.01
Cholesterol (mmol/l) 4.9 (4.1–5.3) 4.3 (3.8–4.8) P  0.05
Triglycerides (mmol/l) 1.0 (0.8–1.7) 0.8 (0.6–1.1) P  0.05
LH (IU/l) 7.8 (4.7–11.0) 3.8 (2.7–5.4) P  0.01
FSH (IU/l) 5.2 (4.0–6.2) 5.7 (4.3–7.5) NS
Testosterone (nmol/l) 1.8 (1.5–2.5) 1.2 (1.0–1.6) P  0.01
Androstenedione (nmol/l) 3.0 (2.3–3.8) 2.6 (1.9–3.6) NS
DHEA-S (mol/l) 4.3 (2.7–5.6) 6.1 (3.8–7.5) P  0.01
SHBG (nmol/l) 27.0 (20.5–41.0) 45.0 (34.0–59.0) P  0.01
FAI 6.6 (4.6–9.7) 3.0 (1.9–4.4) P  0.01
SBP (mmHg) 125.0 (120.0–130.0) 120.0 (110.0–120.0) P  0.01
DBP (mmHg) 80.0 (75.0–80.0) 75.0 (70.0–80.0) P  0.01
IMT (mm) 0.53 (0.48–0.58) 0.42 (0.40–0.44) P  0.01
hs-CRP (mg/l) 3.3 (2.4–5.5) 1.3 (0.5–2.5) P  0.01
Omentin-1 (ng/ml) 23.7 (20.0–27.9) 27.6 (25.6–29.4) P  0.05
Data are median (interquartile range). Group comparison by Mann–Whitney U test. Free androgen index (FAI)  T (nmol/l)/SHBG (nmol/l) 
100. NS  not signiﬁcant; LH, luteinizing hormone; FSH, follicular stimulating hormone; DHEA-S, dehydroepiandrosterone-sulfate; SHBG, sex
hormone–binding globulin; SBP, systolic blood pressure; DBP, diastolic blood pressure.
TABLE 2
Clinical, hormonal, and metabolic features of women with PCOS (n  21) before and after metformin treatment
Variable Before metformin After metformin Signiﬁcance
Age (years) 28 (26.5–31.5) 28 (27.5–32.5) NS
BMI (kg/m
2) 32.8 (29.8–36.5) 31.4 (28.2–35.1) NS
WHR 0.82 (0.76–0.88) 0.80 (0.74–0.87) P  0.05
Glucose (mmol/l) 5.1 (4.7–5.5) 4.8 (4.4–4.9) P  0.05
Insulin (pmol/l) 70.0 (54.5–94.5) 61.0 (43.5–83.0) NS
HOMA-IR 2.2 (2.0–3.0) 1.6 (1.3–2.2) P  0.05
Cholesterol (mmol/l) 4.9 (4.1–5.3) 5.0 (4.1–5.4) NS
Triglycerides (mmol/l) 1.0 (0.8–1.7) 1.2 (1.0–1.9) NS
Testosterone (nmol/l) 1.8 (1.5–2.5) 1.3 (1.1–1.8) P  0.05
Androstenedione (nmol/l) 3.0 (2.3–3.8) 2.8 (2.2–3.6) NS
DHEA-S (mol/l) 4.3 (2.7–5.6) 5.4 (3.6–6.7) NS
SHBG (nmol/l) 27.0 (20.5–41.0) 29.0 (21.5–46.5) NS
FAI 6.6 (4.6–9.7) 5.3 (3.1–6.6) NS
SBP (mmHg) 125.0 (120.0–130.0) 120.0 (120.0–127.5) NS
DBP (mmHg) 80.0 (75.0–80.0) 75.0 (75.0–80.0) NS
IMT (mm) 0.53 (0.48–0.58) 0.47 (0.41–0.53) P  0.05
hs-CRP (mg/l) 3.3 (2.4–5.5) 3.1 (2.0–6.2) NS
Omentin-1 (ng/ml) 23.7 (20.0–27.9) 59.2 (52.1–60.6) P  0.01
Data are median (interquartile range). Group comparison by Mann–Whitney U test. Free androgen index (FAI)  T (nmol/l)/SHBG (nmol/l) 
100. NS  not signiﬁcant; DHEA-S, dehydroepiandrosterone-sulfate; SHBG, sex hormone–binding globulin; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
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in 34 women with PCOS. Only 21 women completed the
study and were investigated after 6 months of metformin
treatment. Reasons for subjects not completing study 2
were nausea and gastrointestinal side effects (n  4),
pregnancies (n  5), incompliance (n  2), and loss of
contact (n  2).
After 6 months of metformin treatment, there was a
signiﬁcant increase in serum omentin-1 [23.7 (20.0–27.9)
versus 59.2 (52.1–60.6) ng/ml; P  0.01: Table 2]. Also,
there were signiﬁcant decreases in waist-to-hip ratio
(WHR), testosterone, glucose, HOMA-IR, and IMT.
Correlation of omentin-1 with covariates. Spearman
rank analyses demonstrated that serum omentin-1 levels
were signiﬁcantly negatively correlated with BMI, WHR,
glucose, HOMA-IR, and hs-CRP (P  0.05). However, when
subjected to multiple regression analysis, none of these
variables were signiﬁcantly negatively correlated with
serum omentin-1 levels (P  0.05).
Furthermore, we analyzed the correlation between the
change in serum omentin-1 levels before and after met-
formin therapy (omentin-1) and the changes () in other
covariates (Table 3). We found that omentin-1 was
signiﬁcantly negatively associated with WHR, glucose,
HOMA-IR, and hs-CRP. When subjected to multiple
regression analysis, only hs-CRP was signiﬁcantly nega-
tively correlated with omentin-1 ( 0.526; P  0.036).
Effects of omentin-1 on in vitro migration and angio-
genesis. Given the above, we studied the effects of
omentin-1 on in vitro migration and angiogenesis. Capil-
lary tube formation was optimal at 24 h, after which
capillary tubes begin to disintegrate. In vitro migration and
angiogenesis at 24 h was signiﬁcantly increased when
comparing sera of PCOS women to normal control sub-
jects (Figs. 1 and 2;
##P  0.01). Also, in vitro migration
and angiogenesis were signiﬁcantly decreased in PCOS
women after 6 months of metformin treatment (Figs. 1 and
2; **P  0.01) and when omentin-1 (200 ng/ml) or the
PI3K/Akt inhibitor (LY294002; 10 mol/l) were added to
sera (Figs. 1 and 2; *P  0.05, **P  0.01). Furthermore,
CRP (1ug/ml) and VEGF (10 ng/ml) induced in vitro
migration, and angiogenesis was signiﬁcantly decreased
by omentin-1 (Figs. 1 and 2; *P  0.05).
Moreover, in vitro migration and angiogenesis were
signiﬁcantly decreased in CRP (PCOS before metformin)
but not signiﬁcantly altered by omentin-1 (PCOS after
metformin) immunodepleted sera (Figs. 1 and 2; P  0.05,
*P  0.05).
Effects of omentin-1 on NF-B activation in human
microvascular endothelial cells. In HMEC-1 cells,
NF-B was signiﬁcantly activated by sera from normal and
PCOS women compared with control subjects (Fig. 3;
#P 
0.05,
##P  0.01). NF-B was signiﬁcantly activated by sera
from PCOS women compared with normal women (Fig. 3;
**P  0.01). Also, NF-B activation was signiﬁcantly
decreased in PCOS women after 6 months of metformin
treatment (Fig. 3; **P  0.01) and when omentin-1 (200
ng/ml) was added to sera (Fig. 3; *P  0.05). Furthermore,
CRP (1 ug/ml) and TNF-	 (10 ng/ml) induced NF-B
activation was signiﬁcantly decreased by omentin-1 (Fig.
3; *P  0.05).
Moreover, NF-B activation was signiﬁcantly decreased
in CRP (PCOS before metformin) but not signiﬁcantly
altered by omentin-1 (PCOS after metformin) immunode-
pleted sera (Fig. 3; P  0.05, *P  0.05).
Effects of omentin-1 on Erk1/2 and Akt signaling
pathways in human microvascular endothelial cells.
In HMEC-1 cells, Erk1/2 and Akt pathways were signiﬁ-
cantly activated by sera from normal and PCOS women
compared with control subjects (Fig. 4A and B;
#P  0.05,
##P  0.01). Erk1/2 and Akt phosphorylation were signiﬁ-
cantly increased by sera from PCOS women compared
with normal women (Fig. 4A and B;* * P  0.01). Also,
Erk1/2 and Akt activation were signiﬁcantly decreased in
PCOS women after 6 months of metformin treatment (Fig.
4A and B;* P  0.05, **P  0.01). Furthermore, Akt
activation was signiﬁcantly decreased when omentin-1
(200 ng/ml) was added to sera from PCOS women before
metformin treatment (Fig. 4B;* P  0.05). However, there
was no signiﬁcant difference in Erk1/2 activation (Fig. 4A).
The detected proteins for phosphorylated Erk1/2, total
Erk1/2, phosphorylated Akt, and total Akthad apparent
molecular weights of 44/42, 44/42, 60, and 60 kDa, respec-
tively (Fig. 4A and B, inserts).
DISCUSSION
We conﬁrm our previous data of decreased circulating
omentin-1 in PCOS women. Also, serum omentin-1 levels
were signiﬁcantly negatively correlated with BMI, WHR,
glucose, HOMA-IR, and hs-CRP. We report that metformin
(6 months treatment; 850 mg twice daily) signiﬁcantly
increases serum omentin-1 levels with concomitant de-
creases in insulin resistance and carotid IMT in PCOS
subjects. Although the change in serum omentin-1 levels
were signiﬁcantly negatively associated with changes in
WHR, glucose, HOMA-IR, and hs-CRP, only the change of
hs-CRP was signiﬁcantly negatively correlated with the
change of serum omentin-1 levels when subjected to
multiple regression analysis. The possible implication is
TABLE 3
Linear regression analysis of variables associated with changes
in serum omentin-1 levels (before and after metformin treat-
ment), omentin-1, in PCOS subjects (n  21)
Variable
Simple Multiple
rP P
BMI (kg/m
2) 0.400 0.072
WHR 0.445 0.043 0.189 0.338
Glucose (mmol/l) 0.471 0.031 0.038 0.906
Insulin (pmol/l) 0.014 0.953
HOMA-IR 0.461 0.035 0.149 0.611
Cholesterol (mmol/l) 0.100 0.667
Triglycerides (mmol/l) 0.390 0.080
Testosterone (nmol/l) 0.126 0.586
Androstenedione (nmol/l) 0.139 0.548
DHEA-S (mol/l) 0.232 0.311
SHBG (nmol/l) 0.131 0.570
FAI 0.200 0.385
SBP (mmHg) 0.222 0.333
DBP (mmHg) 0.032 0.889
IMT (mm) 0.032 0.892
hs-CRP (mg/l) 0.665 0.010 0.526 0.036
Spearman rank correlation was used for calculation of associations
between variables. If individual bivariate correlations achieved sta-
tistical signiﬁcance, multiple regression analysis with omentin-1 as
dependent variable was performed to test the joint effect of these
parameters on omentin-1. Multiple regression analysis contained
WHR, glucose, HOMA-IR, and hs-CRP. DHEA-S, dehydroepiandros-
terone-sulfate; SHBG, sex hormone–binding globulin; FAI, free an-
drogen index; SBP, systolic blood pressure; DBP, diastolic blood
pressure.
OMENTIN-1 AND ANGIOGENESIS
3026 DIABETES, VOL. 59, DECEMBER 2010 diabetes.diabetesjournals.orgthat changes in omentin-1 levels associated with met-
formin treatment observed in our PCOS subjects are more
robustly linked to changes in inﬂammatory rather than
metabolic parameters. Of relevance, there is evidence that
inﬂammatory markers other than CRP are elevated in
PCOS subjects (3–5); also, studies have indicated met-
formin’s potential anti-inﬂammatory effects via modula-
tion of TNF-	, IL-6, IL-18, and IL-1- levels (27–29).
In PCOS women, metformin corrects the associated endo-
crine and metabolic abnormalities (30); metformin counters
IR by inhibiting hepatic glucose production (31–33). There-
fore, glucose may regulate circulating omentin-1 levels; how-
ever, it is possible that the effect of metformin on omentin-1
levels could be via modulation of other circulating factors.
Further studies are needed to clarify this point.
PCOS is a state of altered steroid milieu. We, like others
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FIG. 1. In vitro tube formation by human serum at 24 h from normal control subjects (n  39) with or without omentin-1 (200 ng/ml), PCOS
women (n  21) with or without omentin-1 (200 ng/ml) or PI3K/Akt inhibitor (LY294002; 10 mol/l) or CRP immunodepletion (CRP_IP), PCOS
women after 6 months of metformin treatment (n  21) with or without omentin-1 immunodepletion (Omentin-1_IP), CRP (1ug/ml) with or
without addition of omentin-1 (200 ng/ml) (n  6), and VEGF (10 ng/ml) with or without addition of omentin-1 (200 ng/ml) (n  6), respectively.
Data are expressed as % difference of median of normal control subjects [medians (interquartile range)]. Each experiment was performed in
three replicates. Group comparison by Kruskal–Wallis ANOVA (post hoc analysis: Dunn’s test) and Mann–Whitney U test, respectively.
#P < 0.05,
##P < 0.01; *P < 0.05, **P < 0.01.
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after metformin treatment. However, treatments of omen-
tal adipose tissue explants with gonadal and adrenal
steroids revealed no meaningful effects on omentin-1
levels (13). It is therefore unlikely that the effects of
metformin on serum omentin-1 levels observed in this
study are attributable to altered gonadal and adrenal
steroids.
Furthermore, functional assays revealed that in vitro mi-
gration and angiogenesis were signiﬁcantly increased by sera
from both normal and PCOS women; in PCOS women, in
vitro migration and angiogenesis was attenuated after 6
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FIG. 2. Endothelial cell migration by human serum at 24 h from normal control subjects (n  39) with or without omentin-1 (200 ng/ml), PCOS
women (n  21) with or without omentin-1 (200 ng/ml) or PI3K/Akt inhibitor (LY294002; 10 mol/l) or CRP immunodepletion (CRP_IP), PCOS
women after 6 months of metformin treatment (n  21) with or without omentin-1 immunodepletion (Omentin-1_IP), CRP (1ug/ml) with or
without addition of omentin-1 (200 ng/ml) (n  6), and VEGF (10 ng/ml) with or without addition of omentin-1 (200 ng/ml) (n  6), respectively.
Data are expressed as % difference of median of normal control subjects [medians (interquartile range)]. Each experiment was performed in
three replicates. Group comparison by Kruskal–Wallis ANOVA (post hoc analysis: Dunn’s test) and Mann-Whitney U test, respectively.
#P < 0.05,
##P < 0.01; *P < 0.05, **P < 0.01.
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sera from PCOS women before metformin treatment signif-
icantly decreased in vitro migration and angiogenesis. Omen-
tin-1 also decreased the effects of CRP and VEGF induced in
vitro migration and angiogenesis. However, in vitro migration
and angiogenesis were signiﬁcantly decreased in CRP but not
signiﬁcantly altered by omentin-1 immunodepleted sera. It is
important to consider that omentin-1 levels in tissues are
unknown; the levels are likely to be signiﬁcantly higher than
in sera as sequestration of omentin-1 in vascular tissue, in
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FIG. 3. Effects of serum from normal control subjects (n  39) with or without omentin-1 (200 ng/ml), PCOS women (n  21) with or without
omentin-1 (200 ng/ml) or CRP immunodepletion (CRP_IP), PCOS women after 6 months of metformin treatment (n  21) with or without
omentin-1 immunodepletion (Omentin-1_IP), CRP (1ug/ml) with or without addition of omentin-1 (200 ng/ml) (n  6), and TNF- (10 ng/ml) with
or without addition of omentin-1 (200 ng/ml) (n  6), respectively, on NF-B activation in HMEC-1 cells stably transfected with pNF-B-
luciferase at 2 h. Cells were lysed, and luciferase activities (RLU) were measured. Data are expressed as % difference of median of basal [medians
(interquartile range)]. Each experiment was performed in three replicates. Group comparison by Kruskal–Wallis ANOVA (post hoc analysis:
Dunn’s test) and Mann–Whitney U test, respectively.
#P < 0.05,
##P < 0.01; *P < 0.05, **P < 0.01.
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(10,35). All of these effects appear to be associated with
NF-B and Akt signaling pathways, both well-established
mediators of angiogenesis (36–38). Taken together, increases
in omentin-1 levels may play a role but are not sufﬁcient to
explain the decreased inﬂammatory and angiogenic effects of
sera from metformin-treated PCOS women. It is important to
bear in mind that metformin may also modulate angiogenesis
via the VEGF system. Of relevance, metformin decreases
VEGF levels in type 2 diabetic subjects (39).
The link between angiogenesis and the pathogenesis of
atherosclerosis has been well described (17). Given our
data of an increase in circulating omentin-1 levels with
concomitant decrease in IMT, omentin-1 may have a
potential role in the pathogenesis of atherosclerosis.
Omentin-1, by promoting activation of the Akt signaling
pathway and in turn modulating the endothelial nitric
oxide synthase in endothelial cells, may impact upon
endothelial dysfunction, a step that is crucial in the
pathogenesis of atherosclerosis (40,41). Our novel data of
omentin-1 on angiogenesis in relation to the Akt signaling
pathway thus clariﬁes omentin-1’s potentially important
role in the pathogenesis of cardiovascular disorders.
A limitation of our study may relate to the lack of a lean
PCOS comparator group. Only 3 of the 21 PCOS subjects
and 6 of the 39 control subjects had BMI  25 kg/m
2; thus,
no meaningful result could be obtained. Future studies
should address this point. Furthermore, given ethical
constraints, that is, blood samples could and were only
obtained at baseline and after 6 months of metformin
treatment, it is therefore difﬁcult to be certain as to
whether changes in serum omentin-1 levels precede or
follow changes in clinical and hormonal indexes as a
consequence of metformin treatment. Also, as diet and
lifestyle modiﬁcations were only subjectively assessed, the
changes in serum omentin-1 levels may be partially attrib-
utable to diet and lifestyle modiﬁcations. Further studies
are needed to elucidate this point. Additionally, like others
(42), we used WHR, a universally accepted, simple, and
cost-effective measure of adiposity as a surrogate marker
for central fat mass. However, Cascella et al. has reported
that WHR does not distinguish between visceral and
subcutaneous fat mass in PCOS women (43). Therefore,
more accurate and equally cost-effective methods of as-
sessing central obesity are needed. Finally, given that
PCOS is a proinﬂammatory state associated with cluster-
ing of cardiovascular risk factors, it would be of impor-
tance to study the effect of metformin therapy in the
context of omentin-1 biology on reactive oxygen species in
PCOS women, as reactive oxygen species not only induces
tissue damage and inﬂammation but also is increased in
dysmetabolic states including PCOS (44).
In conclusion, we provide evidence that increases in
omentin-1 levels may play a role but are not sufﬁcient to
explain the decreased inﬂammatory and angiogenic effects of
sera from metformin-treated PCOS women.Our ﬁndings pro-
vide novel insights into the relationship between obesity,
insulin resistance, and metformin therapy with dysregulated
angiogenesis in PCOS women in the context of omentin-1
biology.
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